Use of NSAIDs

References

• Kurata JH, Abbey DE. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. J Clin Gastroenterol 1990; 12(3): 260–6
   PubMed Web of Science ®Google Scholar
• Silvoso GR, Ivey KJ, Butt JH, et al. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med 1979; 91(4): 517–20
   PubMed Web of Science ®Google Scholar
• Roth SH. Nonsteroidal anti-inflammatory drugs: gastropathy, deaths, and medical practice. Ann Intern Med 1988; 109(5): 353–4
   PubMed Web of Science ®Google Scholar
• Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114(4): 257–63
   PubMed Web of Science ®Google Scholar
• Walt R, Katschinski B, Logan R, et al. Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet 1986; 1(8479): 489–92
   PubMed Web of Science ®Google Scholar
• Griffin MR, Ray WA, Schaffner W, et al. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109(5): 359–63
   PubMed Web of Science ®Google Scholar
• Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91(3): 213–22
   PubMed Web of Science ®Google Scholar
• Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114(9): 735–40
   PubMed Web of Science ®Google Scholar
• Hawthorne AB, Mahida YR, Cole AT, et al. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 1991; 32(1): 77–83
   PubMed Web of Science ®Google Scholar
• Soll AH, Weinstein WM, Kurata J, et al. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991; 114(4): 307–19
   PubMed Web of Science ®Google Scholar
• Larkai EN, Smith JL, Lidsky MD, et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82(11): 1153–8
   PubMed Web of Science ®Google Scholar
• Roth S, Bennett R, Caldron P, et al. Reduced risk of NSAID gastropathy (GI mucosal toxicity) with nonacetylated salicylate (salsalate): an endoscopic study. Semin Arthritis Rheum 1990; 19(4 Supp12): 11–9
   PubMed Web of Science ®Google Scholar
• Carson JL, Strom BL, Morse ML, et al. The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs. Arch Intern Med 1987; 147(6): 1054–9
   PubMedGoogle Scholar
• Jeremy JY, Mikhailidis DP, Barradas MA, et al. The effect of nabumetone and its principal active metabolite on in vitro human gastric mucosal prostanoid synthesis and platelet function, Br J Rheumatol 1990; 29(2): 116–9
   PubMedGoogle Scholar
• Friedel HA, Langtry HD, Buckley MM. Nabumetone: a reappraisal of its pharmacology and therapeutic use in rheumatic diseases. Drugs 1993; 45(1): 131–56
   PubMed Web of Science ®Google Scholar
• Roth SH, Tindali EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993; 153(22): 2565–71
   PubMedGoogle Scholar
• Dvornik D, Lee DK. Theoretical mechanism for the gastrointestinal safety of etodolac: selective sparing of cytoprotective prostaglandins. Clin Rheumatol 1989; 8(Suppl 1): 16–24
   PubMed Web of Science ®Google Scholar
• Robert A. Cytoprotection by prostaglandins. Gastroenterology 1979; 77(4 Pt 1): 761–7
   PubMed Web of Science ®Google Scholar
• Lanza FL. A review of mucosal protection by synthetic prostaglandin E analogs against injury by non-steroidal anti-inflammatory agents. Scand J Gastroenterol (Suppl) 1989; 163: 36–43
   PubMedGoogle Scholar
• Ballinger AB, Kumar PJ, Scott DL. Misoprostol in the prevention of gastroduodenal damage in rheumatology. Ann Rheum Dis 1992; 51(9): 1089–93
   PubMed Web of Science ®Google Scholar
• Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988; 2(8623): 1277–80
   PubMed Web of Science ®Google Scholar
• Ehsanullah RS, Page MC, Tildesley G, et al. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988; 297(6655): 1017–21
   PubMed Web of Science ®Google Scholar
• Cryer B, Feldman M. Effects of nonsteroidal anti-inflammatory drugs on endogenous gastrointestinal prostaglandins and therapeutic strategies for prevention and treatment of nonsteroidal anti-inflammatory drug-induced damage. Arch Intern Med 1992; 152(6): 1145–55
   PubMedGoogle Scholar
• Graham DY, lidsky MD, Cox AM, et al. Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection. Gastroenterology 1991; 100(6): 1653–7
   PubMed Web of Science ®Google Scholar
• Loeb DS, Talley NJ, Ahlquist DA, et al. Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: the role of Helicobacter pylori. Gastroenterology 1992; 102(6): 1899–905
   PubMed Web of Science ®Google Scholar
• Hudson N, Balsitis M, Filipowicz F, et al. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993; 34(6): 748–51
   PubMed Web of Science ®Google Scholar
• Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut 1991; 32(3): 252–5
   PubMed Web of Science ®Google Scholar
• Walan A, Bader JP, Classen M, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989; 320(2): 69–75
   PubMed Web of Science ®Google Scholar